Re: The Pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease

Editorial

Alan J Wein. J Urol. 2015 Jan.

. 2015 Jan;193(1):218-9.

doi: 10.1016/j.juro.2014.10.078. Epub 2014 Oct 22.

No abstract available

Comment on

Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A. Abrams P, et al. Eur Urol. 2015 Mar;67(3):577-88. doi: 10.1016/j.eururo.2014.02.012. Epub 2014 Feb 19. Eur Urol. 2015. PMID: 24612659 Clinical Trial.
The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease.
Dale PR, Cernecka H, Schmidt M, Dowling MR, Charlton SJ, Pieper MP, Michel MC. Dale PR, et al. Curr Opin Pharmacol. 2014 Jun;16(100):31-42. doi: 10.1016/j.coph.2014.03.003. Epub 2014 Mar 27. Curr Opin Pharmacol. 2014. PMID: 24682092 Free PMC article. Review.